Neuromodulatory treatments for psychiatric disease: A comprehensive survey of the clinical trial landscape
Background: Numerous neuromodulatory therapies are currently under investigation or in clinical use for the treatment of psychiatric conditions. Objective/hypothesis: We sought to catalogue past and present human research studies on psychiatric neuromodulation and identify relevant trends in this fi...
Main Authors: | , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-09-01
|
Series: | Brain Stimulation |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1935861X21002230 |
id |
doaj-c90204b24ecb401dafbcef8c105a6f64 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Gavin J.B. Elias Alexandre Boutet Roohie Parmar Emily H.Y. Wong Jürgen Germann Aaron Loh Michelle Paff Aditya Pancholi Dave Gwun Clement T. Chow Flavia Venetucci Gouveia Irene E. Harmsen Michelle E. Beyn Emiliano Santarnecchi Alfonso Fasano Daniel M. Blumberger Sidney H. Kennedy Andres M. Lozano Venkat Bhat |
spellingShingle |
Gavin J.B. Elias Alexandre Boutet Roohie Parmar Emily H.Y. Wong Jürgen Germann Aaron Loh Michelle Paff Aditya Pancholi Dave Gwun Clement T. Chow Flavia Venetucci Gouveia Irene E. Harmsen Michelle E. Beyn Emiliano Santarnecchi Alfonso Fasano Daniel M. Blumberger Sidney H. Kennedy Andres M. Lozano Venkat Bhat Neuromodulatory treatments for psychiatric disease: A comprehensive survey of the clinical trial landscape Brain Stimulation Neuromodulation Psychiatry Clinical trials Transcranial magnetic stimulation Deep brain stimulation Transcranial electrical stimulation |
author_facet |
Gavin J.B. Elias Alexandre Boutet Roohie Parmar Emily H.Y. Wong Jürgen Germann Aaron Loh Michelle Paff Aditya Pancholi Dave Gwun Clement T. Chow Flavia Venetucci Gouveia Irene E. Harmsen Michelle E. Beyn Emiliano Santarnecchi Alfonso Fasano Daniel M. Blumberger Sidney H. Kennedy Andres M. Lozano Venkat Bhat |
author_sort |
Gavin J.B. Elias |
title |
Neuromodulatory treatments for psychiatric disease: A comprehensive survey of the clinical trial landscape |
title_short |
Neuromodulatory treatments for psychiatric disease: A comprehensive survey of the clinical trial landscape |
title_full |
Neuromodulatory treatments for psychiatric disease: A comprehensive survey of the clinical trial landscape |
title_fullStr |
Neuromodulatory treatments for psychiatric disease: A comprehensive survey of the clinical trial landscape |
title_full_unstemmed |
Neuromodulatory treatments for psychiatric disease: A comprehensive survey of the clinical trial landscape |
title_sort |
neuromodulatory treatments for psychiatric disease: a comprehensive survey of the clinical trial landscape |
publisher |
Elsevier |
series |
Brain Stimulation |
issn |
1935-861X |
publishDate |
2021-09-01 |
description |
Background: Numerous neuromodulatory therapies are currently under investigation or in clinical use for the treatment of psychiatric conditions. Objective/hypothesis: We sought to catalogue past and present human research studies on psychiatric neuromodulation and identify relevant trends in this field. Methods: ClinicalTrials.gov (https://www.clinicaltrials.gov/) and the International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/) were queried in March 2020 for trials assessing the outcome of neuromodulation for psychiatric disorders. Relevant trials were categorized by variables such as neuromodulation modality, country, brain target, publication status, design, and funding source. Results: From 72,086 initial search results, 1252 unique trials were identified. The number of trials registered annually has consistently increased. Half of all trials were active and a quarter have translated to publications. The largest proportion of trials involved depression (45%), schizophrenia (18%), and substance use disorders (14%). Trials spanned 37 countries; China, the second largest contributor (13%) after the United States (28%), has increased its output substantially in recent years. Over 75% of trials involved non-convulsive non-invasive modalities (e.g., transcranial magnetic stimulation), while convulsive (e.g., electroconvulsive therapy) and invasive modalities (e.g., deep brain stimulation) were less represented. 72% of trials featured approved or cleared interventions. Characteristic inter-modality differences were observed with respect to enrollment size, trial design/phase, and funding. Dorsolateral prefrontal cortex accounted for over half of focal neuromodulation trial targets. The proportion of trials examining biological correlates of neuromodulation has increased. Conclusion(s): These results provide a comprehensive overview of the state of psychiatric neuromodulation research, revealing the growing scope and internationalism of this field. |
topic |
Neuromodulation Psychiatry Clinical trials Transcranial magnetic stimulation Deep brain stimulation Transcranial electrical stimulation |
url |
http://www.sciencedirect.com/science/article/pii/S1935861X21002230 |
work_keys_str_mv |
AT gavinjbelias neuromodulatorytreatmentsforpsychiatricdiseaseacomprehensivesurveyoftheclinicaltriallandscape AT alexandreboutet neuromodulatorytreatmentsforpsychiatricdiseaseacomprehensivesurveyoftheclinicaltriallandscape AT roohieparmar neuromodulatorytreatmentsforpsychiatricdiseaseacomprehensivesurveyoftheclinicaltriallandscape AT emilyhywong neuromodulatorytreatmentsforpsychiatricdiseaseacomprehensivesurveyoftheclinicaltriallandscape AT jurgengermann neuromodulatorytreatmentsforpsychiatricdiseaseacomprehensivesurveyoftheclinicaltriallandscape AT aaronloh neuromodulatorytreatmentsforpsychiatricdiseaseacomprehensivesurveyoftheclinicaltriallandscape AT michellepaff neuromodulatorytreatmentsforpsychiatricdiseaseacomprehensivesurveyoftheclinicaltriallandscape AT adityapancholi neuromodulatorytreatmentsforpsychiatricdiseaseacomprehensivesurveyoftheclinicaltriallandscape AT davegwun neuromodulatorytreatmentsforpsychiatricdiseaseacomprehensivesurveyoftheclinicaltriallandscape AT clementtchow neuromodulatorytreatmentsforpsychiatricdiseaseacomprehensivesurveyoftheclinicaltriallandscape AT flaviavenetuccigouveia neuromodulatorytreatmentsforpsychiatricdiseaseacomprehensivesurveyoftheclinicaltriallandscape AT ireneeharmsen neuromodulatorytreatmentsforpsychiatricdiseaseacomprehensivesurveyoftheclinicaltriallandscape AT michelleebeyn neuromodulatorytreatmentsforpsychiatricdiseaseacomprehensivesurveyoftheclinicaltriallandscape AT emilianosantarnecchi neuromodulatorytreatmentsforpsychiatricdiseaseacomprehensivesurveyoftheclinicaltriallandscape AT alfonsofasano neuromodulatorytreatmentsforpsychiatricdiseaseacomprehensivesurveyoftheclinicaltriallandscape AT danielmblumberger neuromodulatorytreatmentsforpsychiatricdiseaseacomprehensivesurveyoftheclinicaltriallandscape AT sidneyhkennedy neuromodulatorytreatmentsforpsychiatricdiseaseacomprehensivesurveyoftheclinicaltriallandscape AT andresmlozano neuromodulatorytreatmentsforpsychiatricdiseaseacomprehensivesurveyoftheclinicaltriallandscape AT venkatbhat neuromodulatorytreatmentsforpsychiatricdiseaseacomprehensivesurveyoftheclinicaltriallandscape |
_version_ |
1717370821104631808 |
spelling |
doaj-c90204b24ecb401dafbcef8c105a6f642021-09-23T04:37:23ZengElsevierBrain Stimulation1935-861X2021-09-0114513931403Neuromodulatory treatments for psychiatric disease: A comprehensive survey of the clinical trial landscapeGavin J.B. Elias0Alexandre Boutet1Roohie Parmar2Emily H.Y. Wong3Jürgen Germann4Aaron Loh5Michelle Paff6Aditya Pancholi7Dave Gwun8Clement T. Chow9Flavia Venetucci Gouveia10Irene E. Harmsen11Michelle E. Beyn12Emiliano Santarnecchi13Alfonso Fasano14Daniel M. Blumberger15Sidney H. Kennedy16Andres M. Lozano17Venkat Bhat18Division of Neurosurgery, Department of Surgery, University Health Network & University of Toronto, Toronto, Canada; Krembil Research Institute, University of Toronto, Toronto, CanadaDivision of Neurosurgery, Department of Surgery, University Health Network & University of Toronto, Toronto, Canada; Krembil Research Institute, University of Toronto, Toronto, Canada; Joint Department of Medical Imaging, University of Toronto, Toronto, CanadaDivision of Neurosurgery, Department of Surgery, University Health Network & University of Toronto, Toronto, CanadaDivision of Neurosurgery, Department of Surgery, University Health Network & University of Toronto, Toronto, CanadaDivision of Neurosurgery, Department of Surgery, University Health Network & University of Toronto, Toronto, Canada; Krembil Research Institute, University of Toronto, Toronto, CanadaDivision of Neurosurgery, Department of Surgery, University Health Network & University of Toronto, Toronto, Canada; Krembil Research Institute, University of Toronto, Toronto, CanadaDivision of Neurosurgery, Department of Surgery, University Health Network & University of Toronto, Toronto, CanadaDivision of Neurosurgery, Department of Surgery, University Health Network & University of Toronto, Toronto, CanadaDivision of Neurosurgery, Department of Surgery, University Health Network & University of Toronto, Toronto, CanadaDivision of Neurosurgery, Department of Surgery, University Health Network & University of Toronto, Toronto, CanadaSunnybrook Research Institute, Sunnybrook Health Sciences Centre & University of Toronto, Toronto, CanadaDivision of Neurosurgery, Department of Surgery, University Health Network & University of Toronto, Toronto, Canada; Krembil Research Institute, University of Toronto, Toronto, CanadaDivision of Neurosurgery, Department of Surgery, University Health Network & University of Toronto, Toronto, CanadaBerenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, United StatesKrembil Research Institute, University of Toronto, Toronto, Canada; Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, University Health Network, Toronto, Canada; Center for Advancing Neurotechnological Innovation to Application, Toronto, CanadaTemerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, Canada; Department of Psychiatry, University Health Network & University of Toronto, Toronto, CanadaKrembil Research Institute, University of Toronto, Toronto, Canada; Department of Psychiatry, University Health Network & University of Toronto, Toronto, Canada; Centre for Depression & Suicide Studies, St. Michael's Hospital & University of Toronto, Toronto, CanadaDivision of Neurosurgery, Department of Surgery, University Health Network & University of Toronto, Toronto, Canada; Krembil Research Institute, University of Toronto, Toronto, CanadaKrembil Research Institute, University of Toronto, Toronto, Canada; Department of Psychiatry, University Health Network & University of Toronto, Toronto, Canada; Centre for Depression & Suicide Studies, St. Michael's Hospital & University of Toronto, Toronto, Canada; Corresponding author. 399 Bathurst St., MP 7th Floor, Toronto Western Hospital, Toronto, ON M5T 2S8, Canada.Background: Numerous neuromodulatory therapies are currently under investigation or in clinical use for the treatment of psychiatric conditions. Objective/hypothesis: We sought to catalogue past and present human research studies on psychiatric neuromodulation and identify relevant trends in this field. Methods: ClinicalTrials.gov (https://www.clinicaltrials.gov/) and the International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/) were queried in March 2020 for trials assessing the outcome of neuromodulation for psychiatric disorders. Relevant trials were categorized by variables such as neuromodulation modality, country, brain target, publication status, design, and funding source. Results: From 72,086 initial search results, 1252 unique trials were identified. The number of trials registered annually has consistently increased. Half of all trials were active and a quarter have translated to publications. The largest proportion of trials involved depression (45%), schizophrenia (18%), and substance use disorders (14%). Trials spanned 37 countries; China, the second largest contributor (13%) after the United States (28%), has increased its output substantially in recent years. Over 75% of trials involved non-convulsive non-invasive modalities (e.g., transcranial magnetic stimulation), while convulsive (e.g., electroconvulsive therapy) and invasive modalities (e.g., deep brain stimulation) were less represented. 72% of trials featured approved or cleared interventions. Characteristic inter-modality differences were observed with respect to enrollment size, trial design/phase, and funding. Dorsolateral prefrontal cortex accounted for over half of focal neuromodulation trial targets. The proportion of trials examining biological correlates of neuromodulation has increased. Conclusion(s): These results provide a comprehensive overview of the state of psychiatric neuromodulation research, revealing the growing scope and internationalism of this field.http://www.sciencedirect.com/science/article/pii/S1935861X21002230NeuromodulationPsychiatryClinical trialsTranscranial magnetic stimulationDeep brain stimulationTranscranial electrical stimulation |